Selective Intrapartum Chemoprophylaxis of Neonatal Group B Streptococcal Early-Onset Disease. I. Epidemiologic Rationale

Abstract

Between 1973 and 1981, 61 cases of neonatal group B streptococcal early-onset disease occurred among 32,384 infants born at Michael Reese Hospital and Medical Center, Chicago. Forty-one (67%) of the 61 affected infants were bacteremic at birth, implying intrapartum acquisition of infection. No significant deviations from the overall attack rate of 1.9 per 1,000 live births were associated with maternal demographic factors, but increased attack rates were associated with birth weights of ⩽2.5 kg (7.9 per 1,000), rupture of amniotic membranes >18 hr before birth (7.6 per 1,000), and intrapartum fever (6.5 per 1,000). Forty-five (74%) of the 61 affected infants and 15 (94%) of the 16 with fatal outcome had one or more of these three perinatal risk factors. Based on an intrapartum vaginal carriage rate of 16.7% among parturients with perinatal risk factors, an attack rate of 45.5 per 1,000 was estimated for infants born to colonized “high-risk” parturients, a subgroup comprising ∼3% of our obstetric population. These findings provide a compelling epidemiologic rationale for trials of selectiveintrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease.